Petra Pharma Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Petra Pharma General Information
Description
Developer of phosphoinositide (PI) signaling pathways intended to treat cancer and metabolic diseases. The company develops small molecules to target cellular processes to therapeutically impact human health including cell division, growth, trafficking and signaling, enabling doctors to access novel drugs that may help them treat their patients
Contact Information
Website
www.petrapharmacorp.comCorporate Office
- 450 East 29th Street
- Suite 506
- New York, NY 10016
- United States
Corporate Office
- 450 East 29th Street
- Suite 506
- New York, NY 10016
- United States
Petra Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 14-May-2020 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 31-Mar-2020 | Completed | Generating Revenue | |||
| 1. Early Stage VC (Series A) | 06-Jan-2016 | $48M | $48M | Completed | Startup |
Petra Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Petra Pharma Comparisons
Industry
Financing
Details
Petra Pharma Competitors (77)
One of Petra Pharma’s 77 competitors is Centrose, a Venture Capital-Backed company based in Madison, WI.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Unicyte | Venture Capital-Backed | Oberdorf, Switzerland | ||||
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Iovance Biotherapeutics | Corporation | San Carlos, CA | ||||
| Akero Therapeutics | Corporate Backed or Acquired | South San Francisco, CA |
Petra Pharma Patents
Petra Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025231052-A1 | Solid dispersions of 6-chloro-3-[(1r)-1-[3,6-dimethyl-2-(2- methylindazol-5-yl)-4-oxo-chromen-8-yl]ethoxy]pyridine-2-carboxamide | Pending | 01-May-2024 | ||
| WO-2025231053-A1 | Solid forms of 6-chloro-3-[(1r)-1-[3,6-dimethyl-2-(2-methylindazol-5-yl)-4-oxo-chromen-8-yl]ethoxy]pyridine-2-carboxamide | Pending | 01-May-2024 | ||
| WO-2025221919-A1 | (r)-3-(6-chloro-3-((1-(2-cyclopropyl-6-fluoro-3-methyl-4-oxo-4h-chromen-8-yl)ethyl)amino)pyridin-2-yl)-1,2,4-oxadiazol-5(4h)-one as pi3k inhibitor for the treatment of cancer | Pending | 17-Apr-2024 | ||
| AU-2023373670-A1 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease | Pending | 02-Nov-2022 | ||
| AU-2023373671-A1 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease | Pending | 02-Nov-2022 | A61K31/352 |
Petra Pharma Former Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 180 Degree Capital | Hedge Fund | Minority | ||
| ARCH Venture Partners | Venture Capital | Minority | ||
| AbbVie Ventures | Corporate Venture Capital | Minority | ||
| Accelerator Life Science Partners | Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority |
Petra Pharma FAQs
-
When was Petra Pharma founded?
Petra Pharma was founded in 2015.
-
Where is Petra Pharma headquartered?
Petra Pharma is headquartered in New York, NY.
-
What industry is Petra Pharma in?
Petra Pharma’s primary industry is Drug Discovery.
-
Is Petra Pharma a private or public company?
Petra Pharma is a Private company.
-
What is Petra Pharma’s current revenue?
The current revenue for Petra Pharma is .
-
How much funding has Petra Pharma raised over time?
Petra Pharma has raised $75.5M.
-
Who are Petra Pharma’s investors?
180 Degree Capital, ARCH Venture Partners, AbbVie Ventures, Accelerator Life Science Partners, and Alexandria Venture Investments are 5 of 13 investors who have invested in Petra Pharma.
-
Who are Petra Pharma’s competitors?
Centrose, Unicyte, NGM Biopharmaceuticals, Iovance Biotherapeutics, and Akero Therapeutics are some of the 77 competitors of Petra Pharma.
-
When was Petra Pharma acquired?
Petra Pharma was acquired on 14-May-2020.
-
Who acquired Petra Pharma?
Petra Pharma was acquired by Lilly USA.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process